Core Viewpoint - The Hong Kong innovative drug sector is experiencing significant growth, with the Hong Kong Innovative Drug 50 ETF (513780) leading the market with a year-to-date increase of over 112% [2] Group 1: Market Performance - The Hong Kong Innovative Drug 50 ETF (513780) has seen a net inflow of 800 million yuan in the last 20 days, with a total net inflow exceeding 2 billion yuan this year, bringing its latest scale to 2.712 billion yuan [2] - The ETF is noted for having the largest scale and best liquidity among its peers, allowing for T+0 trading [2] Group 2: Composition and Holdings - The index tracked by the Hong Kong Innovative Drug 50 ETF consists solely of innovative drug companies, with major holdings including industry leaders such as CanSino Biologics, Innovent Biologics, WuXi Biologics, BeiGene, China National Pharmaceutical Group, CSPC Pharmaceutical Group, Hansoh Pharmaceutical, WuXi AppTec, and 3SBio [2] Group 3: Future Outlook - CITIC Securities anticipates an increase in innovative drug catalyst events in September, suggesting that the recent technology switch has cleared out short-term speculative money from the sector, which may allow innovative drugs to continue their upward trend after recent adjustments [2]
年内吸金超20亿元！港股创新药50ETF（513780）盘中涨超2%，机构9月看好创新药赛道
Ge Long Hui A P P·2025-09-02 02:35